ADAM19 CRISPR/Cas9 KO Plasmid (m): sc-418986
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ADAM19 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ADAM19 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ADAM19 Antibody (14J12): sc-73687
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ADAM19 CRISPR/Cas9 KO Plasmid (m) | sc-418986 | 20 µg | $397.00 |
Overview
ADAM19 (a disintegrin and metalloproteinase 19) is a membrane-anchored metalloprotease that regulates ectodomain shedding of cell-surface proteins, influencing growth factor and cytokine signaling as well as cell–cell and cell–matrix interactions. In mouse tissues, ADAM19 contributes to developmental programs, including cardiovascular and craniofacial morphogenesis, and modulates inflammatory and remodeling responses. By controlling substrate processing at the plasma membrane, it intersects with pathways governing proliferation, migration, and differentiation, with downstream effects on MAPK/ERK and other signal transduction cascades. Altered ADAM19 activity or expression has been associated with pathological tissue remodeling and fibrosis-relevant phenotypes, making it a useful target for mechanistic studies in disease models.
ADAM19 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Adam19 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Adam19 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Adam19 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ADAM19 protein expression.
This CRISPR knockout system enables efficient generation of Adam19-deficient cell models for investigation of ADAM19 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Adam19 exon(s) critical for ADAM19 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Adam19 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by ADAM19 CRISPR/Cas9 KO Plasmid (m) and ADAM19 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Adam19 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by ADAM19 HDR Plasmid (m) and ADAM19 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Adam19 homology arms to support homology-directed repair at defined Adam19 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.